Munich - Delayed Quote • EUR Annovis Bio Inc (07X.MU) Follow Compare 2.4450 +0.0500 +(2.09%) As of 8:00:52 AM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 07X.MU 1D 5D -19.84% 1M -49.59% 3M -66.04% 6M -65.76% YTD -50.71% 1Y -75.50% 5Y -92.97% All -92.97% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 07X.MU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference Annovis begins treatment of subjects in Alzheimer’s trial Annovis Bio announces first patients entered Phase 3 study of buntanetap Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease Annovis Bio, Inc. Announces Closing of $21 Million Public Offering Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering Annovis Bio, Inc. Announces Proposed Public Offering Annovis Bio granted U.S. patent covering buntanetap Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace